<DOC>
	<DOC>NCT02147886</DOC>
	<brief_summary>- This is an exploratory, randomized, parallel-group, dose escalation and dose-controlled study without a placebo arm. - Eligible patients will be randomized in a 1:1 ratio (double-blind) to receive Cabaletta in 2 doses, once weekly for 22 weeks (total of 24 weeks of treatment).</brief_summary>
	<brief_title>Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease</brief_title>
	<detailed_description />
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Machado-Joseph Disease</mesh_term>
	<criteria>1. Men and women, 18 75 years 2. Clinically diagnosed as MachadoJoseph disease/Spinocerebellar ataxia 3 confirmed by genetic testing 3. With disease stage 2 or less 4. Stable doses of all medications for 30 days prior to study entry and for the duration of the study. 5. Body Mass Index (BMI) â‰¤32 kg/m2. 6. Ability to ambulate with or without assistance 1. Diabetes mellitus type 1 or 2 2. Other major diseases 3. Uncontrolled heart disease, chronic heart failure (CHF). 4. Other neurological diseases. 5. Ataxia derived from any other cause than geneticallyconfirmed spinocerebellar ataxia 6. Presence of psychosis, bipolar disorder, untreated depression 7. History of malignancy (except noninvasive skin malignancy).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bioblast, Randomized, parallel-group, and dose-controlled</keyword>
</DOC>